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Abstract
Background: Alzheimer’s disease (AD) is associated with deposition of amyloid b (Ab) in the brain, which is
reflected by low concentration of the Ab1-42 peptide in the cerebrospinal fluid (CSF). There are at least 15
additional Ab peptides in human CSF and their relative abundance pattern is thought to reflect the production
and degradation of Ab. Here, we test the hypothesis that AD is characterized by a specific CSF Ab isoform pattern
that is distinct when comparing sporadic AD (SAD) and familial AD (FAD) due to different mechanisms underlying
brain amyloid pathology in the two disease groups.
Results: We measured Ab isoform concentrations in CSF from 18 patients with SAD, 7 carriers of the FAD-
associated presenilin 1 (PSEN1) A431E mutation, 17 healthy controls and 6 patients with depression using
immunoprecipitation-mass spectrometry. Low CSF levels of Ab1-42 and high levels of Ab1-16 distinguished SAD
patients and FAD mutation carriers from healthy controls and depressed patients. SAD and FAD were characterized
by similar changes in Ab1-42 and Ab1-16, but FAD mutation carriers exhibited very low levels of Ab1-37, Ab1-38
and Ab1-39.
Conclusion: SAD patients and PSEN1 A431E mutation carriers are characterized by aberrant CSF Ab isoform
patterns that hold clinically relevant diagnostic information. PSEN1 A431E mutation carriers exhibit low levels of
Ab1-37, Ab1-38 and Ab1-39; fragments that are normally produced by g-secretase, suggesting that the PSEN1
A431E mutation modulates g-secretase cleavage site preference in a disease-promoting manner.
Background
Pathological hallmarks of Alzheimer’s disease (AD)
include synaptic and neuronal degeneration along with
extracellular deposits of amyloid b protein (Ab) in senile
plaques in the cerebral cortex [1]. These changes are
reflected in vivo by elevated tau protein concentrations
and reduced levels of the aggregation prone 42 amino
acid isoform of Ab (Ab1-42) in the cerebrospinal fluid
(CSF) [2,3]. The mechanism underlying CSF Ab1-42
reduction in AD is thought to be sequestration of the
peptide in senile plaques. Accordingly, studies have
found a strong correlation between low Ab1-42 in CSF
and high numbers of plaques in the neocortex and hip-
pocampus [4], as well as high retention of Pittsburgh
Compound-B (PIB) in positron emission tomography
(PET) scans that directly reflect plaque pathology in the
brain [5,6]. Ab peptides are generated through proteoly-
tic processing of the transmembrane amyloid precursor
protein (APP). In the amyloidogenic pathway, APP is
cleaved by two aspartyl proteases, first by b-secretase
within its ectodomain and subsequently by g-secretase
within its transmembrane domain [7]. Certain forms of
Ab1-42 may act early in the disease process by disrupt-
ing synaptic plasticity mechanisms that are believed to
underlie memory in the hippocampal network [8,9].
g-Secretase is a multiprotein complex with the prese-
nilin (PS) proteins at its enzymatic core [10]. Because of
imprecise cleavage specificity, g-secretase generates Ab
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peptides of variable length at the carboxyl terminus.
Mutations in the PS-encoding PSEN1 and PSEN2 genes
that accelerate brain amyloid plaque pathology and
cause early onset familial AD (FAD) increase the Ab1-
42/Ab1-40 ratio in primary fibroblasts and plasma of
affected individuals, in transfected cells, and in trans-
genic animals, but this effect is modest and not always
reproducible [11,12]. To date, more than 160 distinct
AD-promoting missense mutations have been identified
in PSEN1 and three in PSEN2.
In addition to Ab1-42 and Ab1-40, there are several
shorter isoforms of Ab [13]. We recently identified a set
of 18 N- and C-terminally truncated Ab peptides in CSF
using immunoprecipitation-mass spectrometry (IP-MS)
[14,15]. Their relative abundance pattern distinguished
AD from controls with an accuracy of 86% [16]. Here,
we test the hypotheses that (i) sporadic AD patients are
different from controls and patients with depression
with regards to their CSF Ab isoform pattern, (ii) SAD
patients and FAD mutation carriers differ in their Ab
isoform pattern as a reflection of different mechanisms
underlying brain amyloid deposition in the two disease
groups, and (iii) the AD-associated Ab1-16 fragment
affects hippocampal synaptic plasticity.
Results and Discussion
Patient characteristics
Study participants were recruited at three specialized
memory clinics, one in Munich, Germany, and two in
California in the USA (UCSD and UCLA). The Munich
study groups included 6 patients with SAD and 6
patients with major depression. The California study
groups were comprised of 7 subjects carrying the FAD-
associated PSEN1 A431E mutation, 12 patients with
SAD and 17 healthy controls (Table 1). The A431E
mutation in persons of Mexican origin represents a
founder effect arising from Jalisco State [17,18]. This
mutation causes an aggressive form of AD with a mean
age of onset in the early 40’s that is sometimes asso-
ciated with spastic tetraparesis and “cotton-wool” amy-
loid plaques on pathology [19]. Of the 7 PSEN1 A431E
mutation carriers, 5 were completely asymptomatic
(CDR scores of 0) and had a mean age of 26 years,
whereas the other two had some degree of cognitive
impairment (CDR scores of 0.5 and 2, respectively,
Table 2). Prior studies have demonstrated that this
mutation is associated with increased levels of Ab1-42
in the plasma of presymptomatic persons and a
decreased Ab1-42/Ab1-40 ratio in CSF [20].
CSF Ab isoform patterns are distinct across groups
Representative CSF Ab isoform mass spectra for SAD
patients, FAD mutation carriers and controls are shown
in Figure 1. Normalized CSF Ab isoform intensities (Fig-
ure 2) were compared across the three groups using
multivariate discriminant analysis (Figure 3). FAD
patients were clearly separated from SAD and non-AD
(controls and depression), and the latter two groups
were also segregated from each other, although to a les-
ser extent. In order to ease the interpretation, subse-
quent pairwise discriminant analysis were performed for
SAD patients vs. non-AD and SAD vs. FAD. Low levels
of Ab1-42 and high levels of Ab1-16 were the main
contributors for the separation of SAD from non-AD
(Figure 4). Ab1-34, Ab1-17, Ab1-13 and Ab1-14 con-
tributed weakly to the separation. Low CSF Ab1-42 is a
well-replicated finding in AD [21]. However, elevated
Ab1-16 in AD is less well known. The data presented
herein, along with earlier results from independent data
sets [16], show that SAD patients tend to express high
levels of Ab1-16 in their CSF at the group level, which
also seems to hold true for PSEN1 A431E mutation car-
riers (Figure 2). Two SAD patients had very high Ab1-
16 levels (Figure 2). These patients, one male and one
female, were 77 and 79 years old and did not differ
from other SAD patients with regards to cognitive
scores or Ab1-42 concentrations. The reason for their
very high Ab1-16 levels is at present unknown.
Recent cell culture experiments using different secre-
tase inhibitors suggest that Ab1-16 is derived from con-
certed cleavages of APP by b - and a-secretase, thus
reflecting a third metabolic pathway for APP [22]. Cur-
iously, depressed patients in this study also had higher
Ab1-16 levels than the healthy controls (Figure 2).
Pending confirmation in independent and larger patient
materials, this result may provide clues regarding altered
APP metabolism in depression. There were no other
Ab-related changes in common in depression and SAD
vs. controls.
FAD mutation carriers express low levels of Ab1-37, Ab1-
38 and Ab1-39 in CSF
The reason for the distinct subgrouping of SAD patients
and FAD mutation carriers in Figure 3A was analyzed
in detail by comparing their CSF Ab isoform patterns
specifically (Figure 5A). Both disease groups were char-
acterized by similar levels of Ab1-42 and Ab1-40, imply-
ing similar degrees of amyloid pathology in their brains
[4,5]. However, FAD mutation carriers had very low
concentrations of Ab1-37, Ab1-38 and Ab1-39 and high
Ab1-20 compared with SAD patients (Figure 2). These
deviations separated the two groups completely (Figure
5B and 5C). Similar Ab1-37, Ab1-38 and Ab1-39
changes have been seen in media from cell lines expres-
sing the PSEN1 Δ9 or L166P mutation, or the PSEN2
N141I mutation [11]. The Ab1-37, Ab1-38 and Ab1-39
isoforms are normally produced by g-secretase, suggest-
ing that certain PSEN1 and PSEN2 mutations may mod-
ulate g-secretase function by inhibiting cleavage at
Gly37, Gly38 and Val39, without affecting the
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production of Ab1-42 and Ab1-40 significantly. It is
tempting to speculate that Ab1-37, Ab1-38 and Ab1-39
may inhibit Ab1-42 oligomerization by forming less
aggregation-prone heterocomplexes with Ab1-42. Such a
protective effect has recently been described for Ab1-40
[23,24]. The key AD-promoting effect of PSEN1 A431E,
and possibly several other FAD-associated PSEN muta-
tions, may thus be a tweaked g-secretase cleavage site
preference that results in loss of C-terminally truncated
Ab species. Modulating g-secretase function to boost
cleavages at Gly37, Gly38 and Val39 would in that case
be a novel approach to prevent AD-associated Ab aggre-
gation. However, prior to such a claim, the hypothesis
that Ab1-37, Ab1-38 and Ab1-39 indeed inhibit Ab1-42
oligomerization and toxicity must be tested in additional
studies.
AD-associated Ab1-16 does not inhibit long-term
potentiation
One of the hallmark synaptotoxic effects of Ab1-42 is
the inhibition of long-term potentiation (LTP) [25].
Results presented here, together with earlier data from
our group [16], showing elevated CSF levels of Ab1-16
in AD, prompted us to test whether the Ab1-16 peptide
per se inhibits LTP. To that end, we exposed acute rat
hippocampal slices to Ab1-16 and elicited LTP at the
glutamatergic synapses in the CA1 region. Under our
control conditions, a strong LTP-inducing protocol
(three times 20 impulses at 50 Hz during blockade of
GABAA receptors) resulted in LTP that amounted to
130 ± 7.3% (presynaptic volley = 97 ± 3.5%, n = 7) 60
minutes after the induction (Figure 6A, D). As a positive
control, we exposed the slice to Ab1-42 oligomers (pre-
pared from 1 μM monomeric Ab1-42, see Methods) for
30-60 minutes before the induction of LTP. Under these
conditions the LTP was 103 ± 5.9% (presynaptic volley
= 90.5 ± 1.6%, n = 6), which was significantly smaller
than control (P = 0.017) (Figure 6B, D). To test whether
Ab1-16 affects the generation of LTP, we exposed the
slice to Ab1-16 (1 μg/L) for 60 minutes before the
induction. The absolute endogenous concentration of
Ab1-16 in human CSF is 10-50 ng/L [15], but the
synaptic concentration is not known. Therefore, to
ascertain a not too low synaptic concentration of Ab1-
16, we used a concentration 20-100 times the absolute
endogenous concentration of Ab1-16 in human CSF. In
the presence of Ab1-16, LTP was 141 ± 3.6% (presynap-
tic volley = 100 ± 2.5%, n = 12) (Figure 6C, D), which is
not significantly different from the control (P = 0.12).
Hence, we conclude that Ab1-16 does not inhibit LTP
at hippocampal CA3-CA1 synapses.
Limitations
Although the findings of this study are intriguing, there
are some limitations that should be mentioned.
First, the study is small and the important findings, i.
e., the increased levels of Ab1-16 in AD and depression
and the reduced levels of Ab1-37, Ab1-38 and Ab1-39
in PSEN1 A431E-caused FAD, are in need of replication.
Second, CSF samples were obtained at different cen-
ters. However, no center effects on Ab isoform levels
were detected. Further, when levels of the various Ab
peptides were compared between the 7 FAD mutation
carriers and their 3 similarly aged non-mutation carry-
ing kin from whom CSF was obtained at the same cen-
ter, levels of Ab1-37, Ab1-38 and Ab1-39 but not of
other Ab peptides were significantly lower (P ≤ 0.003)
and non-overlapping. In fact, differences in these levels
were greater than that of Ab1-42, which was non-signif-
icant in this small subpopulation. The finding of
decreased levels of Ab1-37, Ab1-38 and Ab1-39 in the
CSF of persons with the A431E PSEN1 mutation there-
fore appears to be a robust finding. How this might be
related to the cotton wool plaque pathology that has
Table 1 Demographic characteristics of patients and controlsa
SAD patients (n = 18) PSEN1 A431E





Age (years) 74 (8.9) 33 (10) 55 (17) 68 (4.9)
Gender (m/f) 10/8 3/4 7/10 0/6
MMSE scoresb 22 (4.4) 24 (9.1) 30 (0.5) 28 (1.9)
aData are presented as mean (standard deviation, SD).
bMMSE is Mini-Mental State Examination score.







1 3/3 -16 0 29
2 3/3 -1 0.5 27
3 3/3 -18 0 29
4 3/3 2 2 5
5 3/3 -22 0 30
6 2/3 -19 0 28
7 2/3 -15 0 29
aRelative age is the number of years prior to the typical family-specific age of
dementia diagnosis. Absolute age and gender are not shown to protect
confidentiality with regard to subjects’ identity and mutation status.
bCDR is the Clinical Dementia Rating scale score (0 = asymptomatic, 0.5 is
questionable dementia, 1 = mild dementia, 2 = moderate dementia, 3 =
severe dementia.
cMMSE is Mini-Mental State Examination score.
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been demonstrated to consist of increased amounts of
N-terminally truncated forms of Ab42 in persons with
other PSEN1 mutations [26] is unclear.
Third, the age distribution differed between the differ-
ent groups. Of all the Ab isoforms, in all study groups,
only Ab1-34 in the controls correlated with age (rs =
-0.61, P = 0.01). However, Ab1-34 is higher in the AD
group compared with the controls, which is opposite to
what would have been expected if the difference were
due to an age effect. This makes age an unlikely
confounder.
Conclusions
The findings presented here show that (i) SAD patients
differ from cognitively normal individuals and depressed
patients with regards to their CSF Ab isoform pattern
and (ii) carriers of the FAD-associated PSEN1 A431E
mutation have low CSF levels of C-terminally truncated
Ab peptides shorter than Ab1-40, suggesting a loss of
function effect that leads to a relative abundance of
aggregation-prone Ab1-42. The influence of Ab1-37,
Ab1-38 and Ab1-39 reductions on Ab1-42 oligomeriza-
tion and toxicity needs to be examined in experimental
studies. CSF Ab1-16 may be a positive biomarker for




Patients with SAD and major depression were diagnosed
according to DSM-IIIR criteria [27]. SAD patients ful-
filled the criteria of probable AD defined by NINCDS-
ADRDA (National Institute of Neurological and Com-
municative Disorders - Stroke/Alzheimer’s Disease and
Related Disorders Association) [28]. The seven persons
carrying the A431E mutation in PSEN1 [17] were parti-
cipants in a study of symptomatic persons affected by (n
= 2), and asymptomatic persons at-risk for (n = 5) FAD
Figure 1 Representative mass spectra showing C-terminally truncated Ab peptides immunoprecipitated from cerebrospinal fluid using
antibody 6E10. (A) Representative Ab isoform pattern in a control individual. (B) Representative Ab isoform pattern in a patient with sporadic
Alzheimer’s disease. (C) Representative Ab isoform pattern in a carrier of the FAD-associated PSEN1 A431E mutation.
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Figure 2 Scatter plots of normalized Ab fragment intensities derived from IP-MS in the different disease and control groups. Thin
horizontal lines indicate medians. Significant differences are indicated.
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being conducted at UCLA. Subjects seen at UCLA
underwent a comprehensive clinical evaluation by inves-
tigators blind to their genetic status that included the
Clinical Dementia Rating scale [29]. Three of the 17
controls were non-mutation carrying family members
also enrolled in this study. The healthy controls were
mainly recruited from senior citizen organizations and
through information meetings on dementia. A few con-
trols were spouses of subjects in the study. Inclusion
criteria for controls were that they should be physically
and mentally healthy and not experiencing or exhibiting
any cognitive impairment. All controls were thoroughly
interviewed about their somatic and mental health by
researchers before inclusion in the study. Mini-mental
state examination (MMSE) was used as a global measure
of cognitive functioning [30]. The study was approved
by the ethics committees of Ludwig-Maximilian Univer-
sity, Germany, and UCLA and UCSD, USA.
Figure 3 Distinct Ab isoform patterns in FAD compared to SAD and non-AD. The figure shows OPLS-DA on the three classes FAD, SAD,
and non-AD (controls and depression) using the data shown in figure 2. (A) Score plot for FAD (open diamonds), SAD (open circles), depression
(solid squares), and controls (solid triangles). (B) Loading and plot for the Ab fragments.
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Figure 4 The Ab isoform pattern separates SAD from controls
and depressed patients. The figure shows OPLS-DA on the two
classes SAD and non-AD (controls and depression) using the data
shown in figure 2. (A) Score plot for SAD (open circles), depression
(solid squares) and controls (solid triangles). (B) Loading and (C)
variable importance on projection (VIP) plots for the Ab fragments.
The error bars in (C) represent a 95% confidence interval.
Figure 5 Distinct Ab isoform patterns in FAD and SAD. The
figure shows OPLS-DA on the two classes SAD and FAD using the
data shown in figure 2. (A) Score plot for FAD (open diamonds) and
SAD (open circles). (B) Loading and (C) variable importance on
projection (VIP) plots for the Ab fragments. The error bars in (C)
represent a 95% confidence interval.
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CSF sampling and biochemical analyses
CSF samples were collected in the morning by lumbar
puncture (LP) through the L3/L4 or L4/L5 interspace.
CSF was collected in polypropylene tubes in 500 μL ali-
quots that were centrifuged, frozen and stored at -80°C
pending biochemical analyses, without being thawed and
re-frozen. The immunoprecipitation and mass spectro-
metric analysis were conducted as described before [15].
Briefly, 8 μg of the monoclonal antibody 6E10 (epitope
4-9, Signet Laboratories Inc., Dedham, USA) was used
together with magnetic Dynabeads (Sheep anti-mouse
IgG) for immunoprecipitating C-terminally truncated
Ab peptides from 1 mL CSF. The samples were analyzed
by matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOFMS, Autoflex,
Bruker Daltonics, Bremen, Germany) operating in reflec-
tor mode. An in house MATLAB® program (Mathworks
Inc. Natick, MA, USA) was used for integration of the
peaks for each spectrum and the integration limits were
from-2 to +5 m/z relative to the monoisotopic peak.
Prior to the statistical analysis the peak areas were nor-
malized to the sum of the integrated peaks.
Electrophysiology
Electrophysiological experiments were performed on
hippocampal slices from 35-60 day-old male Wistar rats.
The rats were anesthetized with isoflurane (Abbott)
prior to decapitation. The brain was removed and
placed in an ice-cold solution containing (in mM): 140
cholineCl, 2.5 KCl, 0.5 CaCl2, 7 MgCl2, 25 NaHCO3,
1.25 NaH2PO4, 1.3 ascorbic acid and 7 dextrose. Trans-
verse hippocampal slices (400 μm thick) were cut with a
vibratome (HM 650 V Microm, Germany) in the same
ice-cold solution and were subsequently stored in artifi-
cial cerebrospinal fluid (ACSF) containing (in mM): 124
NaCl, 3 KCl, 2 CaCl2, 4 MgCl2, 26 NaHCO3, 1.25
NaH2PO4, 0.5 ascorbic acid, 3 myo-inositol, 4 D, L-lactic
acid, and 10 D-glucose. After at least one hour of sto-
rage at 25°C, a single slice was transferred to a recording
chamber where it was kept submerged in a constant
flow (~2 ml min-1) at 30-32°C. The perfusion fluid
Figure 6 Ab1-16 does not inhibit hippocampal long-term potentiation (LTP). (A) Control LTP elicited by three trains (20 impulses, 50 Hz)
separated by 5 seconds. Data points are normalized field EPSP initial slope measurements ± standard errors of the mean. Average (n = 20) field
EPSPs before and 60 minutes after the induction of LTP are shown on top. (B) LTP elicited in the presence of oligomerized Ab1-42 (positive
control). (C) LTP elicited in the presence of Ab1-16. Scale bars represent 5 ms and 0.1 mV. (D) Comparison between LTP 60 minutes after the
induction in control, in Ab1-16 and in Ab1-42.
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contained (in mM) 124 NaCl, 3 KCl, 4 CaCl2, 4 MgCl2,
26 NaHCO3, 1.25 NaH2PO4, and 10 D-glucose. Picro-
toxin (100 μM, Sigma-Aldrich Stockholm, Sweden) was
always present in the perfusion fluid to block GABAA
receptor-mediated activity. All solutions were continu-
ously bubbled with 95% O2 and 5% CO2 (pH ~7.4). The
higher than normal Ca2+ and Mg2+ concentrations were
used to inhibit spontaneous network activity. ACSF was
spiked with synthetic Ab1-16 (Bachem, Weil am Rhein,
Germany) in water solution to a final concentration of 1
μg/L. Ab1-42 oligomers were prepared according to a
standard protocol [31]. Briefly, 1 μM Ab1-42 was dis-
solved in 1,1,1,3,3,3-hexofluoro-2-propanol (HFIP) on
ice and incubated for 90 minutes in room temperature.
HFIP was removed using speedvac and the remaining
Ab1-42 peptide film was stored at -80°C. The film was
dissolved in DMSO to 5 mM, sonicated, further diluted
in PBS containing 0.2% SDS to 400 μM and incubated
for six hours at 37°C. Water was added to a concentra-
tion of 100 μM and this solution was incubated for 18
hours at 37°C. Finally, the solution was centrifuged at
3000 g for 20 minutes and stored for no more than
three days at 4°C.
Electrical stimulation of Schaffer collateral/commis-
sural axons and recordings of synaptic responses were
carried out in the stratum radiatum of the CA1 region.
Stimuli consisted of biphasic constant current pulses (15-
80 μA, 200 μS, STG 1002 Multi Channel Systems MCS
Gmbh, Reutlingen, Germany) delivered through tungsten
wires (resistance ~0.1 MΩ). The synaptic input was acti-
vated every 5 s. Field excitatory postsynaptic potentials
(EPSPs) were recorded with a glass micropipette (1 M
NaCl, resistance ~4 MΩ). Field EPSPs were sampled at
10 kHz with an EPC-9 amplifier (HEKA Elektronik, Lam-
brecht, Germany) and filtered at 1 kHz. Evoked responses
were analyzed off-line using custom-made IGOR Pro
(WaveMetrics, Lake Oswego, OR) software. Field EPSP
magnitude was estimated by linear regression over the
first 0.8 ms of the initial slope. The presynaptic volley
was measured as the slope of the initial positive-negative
deflection, and it was not allowed to change by more
than 15% during the experiment.
Statistical analyses
Multivariate discriminant analysis (DA) was performed
using the orthogonal projection to latent structure
(OPLS) algorithm [32] implemented in the software
SIMCA P+ v. 12 (Umetrics, Umeå, Sweden). In general,
OPLS-DA finds the direction (score vector) in the multi-
dimensional orthogonal space created by the different
measured variables that best separate the predefined
classes. To visualize the result from an OPLS-DA, the
observations are projected onto a plane spanned by the
score vectors. The contribution of the different variables
to the score vectors is presented in a loading plot. A
vector from the origin to a variable in the loading plot
points in the direction that an observation in the score
plot will be displaced if the value of the variable is
increased. Also, the extent of the displacement is propor-
tional to the magnitude of the vector [33]. Comparisons
between groups with regards to individual, normalized
Ab isoform intensities were performed using nonpara-
metric Kruskal-Wallis test, followed by the Mann-Whit-
ney test. P-values for the Mann-Whitney test were
reported given that (i) the p-value for the Kruskal-Wallis
was below 0.05 after Bonferroni correction (15 tests) and
(ii) the difference was significant at p < 0.05 using Dunn’s
post hoc test for multiple comparisons. Electrophysiolo-
gical data were evaluated using Student’s t-test.
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